WESTLAKE VILLAGE, CA – April 27, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced that its ClearID Total Insight Breast Cancer monitoring program will be featured at The American Society of Breast Surgeons Annual Meeting 2017 (booth #114). The event will be held at the Bellagio Resort in Las Vegas, NV from April 26 through April 30, 2017.
ClearID® Total Insight™ Breast Cancer is a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer. The information provided by the ClearID Total Insight monitoring program can aid physicians in drug selection, risk assessment, treatment stratification, evaluation of drug resistance, and selection of monitoring frequency for their patients.
About the American Society of Breast Surgeons
The American Society of Breast Surgeons is the primary leadership organization for general surgeons and breast surgery specialists who treat patients with breast disease and works to improve the practice of breast surgery by serving as an advocate for surgeons who seek excellence in the care of breast patients. Learn more at www.breastsurgeons.org.
About Cynvenio Biosystems, Inc.
Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California (Los Angeles). For more information, please visit www.cynvenio.com, www.clearidmonitoring.com and www.liquidbiopsy.com.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.